A Randomized Comparison of Cilostazol Versus Ticlopidine Therapy After Elective Coronary Stent Implantaion

Background：Percutaneous transluminal coronary angioplasty (PTCA) is a widely acceptable treatment for ischemic heart disease.However, restenosis after successful PTCA, which develops in 20-30% of all patients, remains a serious late complication.This study was performed to compare the efficacy of cilostazol with that of ticlopidine for the prevention of stent restenosis.Materials and Methods：Fifty three patients who had undergone coronary stent implantation were divided into group A (n＝25) receiving 100 mg aspirin and 200 mg cilostazol and group B (n＝28) receiving 100 mg aspirin and 500 mg ticlopidine, between Sep 1998 and Feb 1999 at Pusan Paik Hospital, Inje University.Clinical and laboratory evaluations were preformed at regular intervals.Results：There were no differences in baseline characteristics between the two groups.Coronary artery restenosis was observed in 5 (20.8%) patients of group A and 8 (26%) of group B, a difference which was not statistically significant (p＝NS).The minimal luminal diameter was 2.10±0.89mm in group A and 1.93±0.65 mm in group B (p＝NS).Two patients in group A complained of headaches, while 6 (21.4%) patients of group B developed side effects including thrombocytopenia in 2 patients, and skin rash in 2 patients (Ed-what of the remaining 2 patients with side effects in group B?).No instances of cardiac death occurred during the follow-up period.Conclusion：The findings of this study suggest that aspirin plus cilostazol may be a safer as well as an qually antithrombotic regimen, compared to that of aspirin plus ticolpidine, for recovery after elective coronary stent implantation.(( ( (Korean Circulation J 2001 ; 31( ( ( (8) ) ) ) : 780-787) ) ) ) KEY WORDS：Coronary artery stent•Restenosis•Cilostazol•Ticlopidine.